Initial Positive Top-Line Results Presented on NX Prenatal’s NeXsome Preterm Birth Risk Assay in Women at 10-12 Weeks of Gestation

NX Prenatal Inc., a US-based molecular diagnostics company utilizing its proprietary NeXosome® technology for early warning of adverse pregnancy outcomes, announced today the presentation of its most recent study by Dr. Thomas McElrath of Boston’s Brigham & Women's Hospital at the Society for Maternal Fetal Medicine's (SMFM) annual meeting held inAtlanta, Georgia, February 1-6, 2016. The presentation reported initial positive top-line results regarding the development and continued validation of NX Prenatal's NeXosome Preterm Birth Risk Assay. In a blinded, peer-reviewed process, the SMFM selected this study entitled "Circulating Microparticles As an Effective Means to Stratify the Risk of Spontaneous Preterm Birth" for oral presentation during its annual meeting. This new collaborative study of 75 pregnant mothers was designed to identify functional proteomic biomarkers that are already unique in their expression profiles at 10-12 weeks gestation among women who go on to deliver spontaneously at less than 34 weeks. In pregnancy, the analysis of the protein content of circulating microparticles, such as exosomes, is of believed to be of revolutionary potential as it represents a non-invasive “biopsy” of active gestational tissues. "The NeXosome platform offers a unique opportunity to assess biomarkers related to the network of inter-related systems of the mom and baby that must stay in balance during pregnancy," commented Dr. McElrath. "Interestingly, our findings suggest that we can find irregularities in these networks long before eventual spontaneous preterm birth from a maternal blood sample." "Plans are underway already to validate these findings in subsequent patient cohorts," said Brian Brohman, CEO of NX Prenatal.
Login Or Register To Read Full Story